These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18783292)

  • 1. AKT1 (E17K) mutation in pancreatic cancer.
    Mohamedali A; Lea NC; Feakins RM; Raj K; Mufti GJ; Kocher HM
    Technol Cancer Res Treat; 2008 Oct; 7(5):407-8. PubMed ID: 18783292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
    Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
    Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.
    Cohen Y; Shalmon B; Korach J; Barshack I; Fridman E; Rechavi G
    Gynecol Oncol; 2010 Jan; 116(1):88-91. PubMed ID: 19853286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
    Landgraf KE; Pilling C; Falke JJ
    Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma.
    Zilberman DE; Cohen Y; Amariglio N; Fridman E; Ramon J; Rechavi G
    Cancer Genet Cytogenet; 2009 May; 191(1):34-7. PubMed ID: 19389506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
    BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT Inhibition in Solid Tumors With AKT1 Mutations.
    Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
    J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
    Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
    Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro.
    Chung HW; Wen J; Lim JB; Bang S; Park SW; Song SY
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):862-9. PubMed ID: 19801102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shiratori K; Kawamura S; Kobayashi M; Shimizu M; Ban S; Koyama I; Higashi M; Shin N; Ishida K; Morikawa T; Motoi F; Unno M; Kanno A; Satoh K; Shimosegawa T; Orikasa H; Watanabe T; Nishimura K; Harada Y; Furukawa T
    Am J Surg Pathol; 2011 Dec; 35(12):1812-7. PubMed ID: 21945955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/Akt pathway mutations in retinoblastoma.
    Cohen Y; Merhavi-Shoham E; Avraham-Lubin BC; Savetsky M; Frenkel S; Pe'er J; Goldenberg-Cohen N
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5054-6. PubMed ID: 19420344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
    Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
    Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
    De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
    Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
    Veit C; Genze F; Menke A; Hoeffert S; Gress TM; Gierschik P; Giehl K
    Cancer Res; 2004 Aug; 64(15):5291-300. PubMed ID: 15289335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
    Carpten JD; Faber AL; Horn C; Donoho GP; Briggs SL; Robbins CM; Hostetter G; Boguslawski S; Moses TY; Savage S; Uhlik M; Lin A; Du J; Qian YW; Zeckner DJ; Tucker-Kellogg G; Touchman J; Patel K; Mousses S; Bittner M; Schevitz R; Lai MH; Blanchard KL; Thomas JE
    Nature; 2007 Jul; 448(7152):439-44. PubMed ID: 17611497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel AKT3 mutation in melanoma tumours and cell lines.
    Davies MA; Stemke-Hale K; Tellez C; Calderone TL; Deng W; Prieto VG; Lazar AJ; Gershenwald JE; Mills GB
    Br J Cancer; 2008 Oct; 99(8):1265-8. PubMed ID: 18813315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.